Neal D. Shore, MD, FACS, sits down with CTA to discuss PROSTVAC as a targeted immunotherapy for prostate cancer.
[Cancer Control] Research derived from phase 1 clinical trials can be vital to the development of new treatments. There are long-lasting positive and negative impacts on those patients who choose to participate in phase 1 clinical trials, but participant safety is a priority.
Palliative Care in Oncology Symposium: Limited time, support, and case management among barriers that hinder ability to provide palliative care.
Palliative Care in Oncology Symposium: Dispositional mindfulness may promote flourishing when confronting cancer.
Palliative Care in Oncology Symposium: Palliative care for non-small cell lung cancer may not increase healthcare costs in the last 30 days of life.
Palliative Care in Oncology Symposium: Clinicians utilize six key elements, four longitudinal approaches and three specific techniques.
Addition of pertuzumab to traztuzumab + docetaxel added almost 16 months to overall survival compared to those who didn't receive pertuzumab.
Palliative Care in Oncology Symposium: Combination netupitant + palonosetron improves delayed phase nausea in highly emetic chemotherapy.
Palliative Care in Oncology Symposium: E-mail trigger for advanced care planning in the outpatient oncology clinic effective in prompting conversations.
Palliative Care in Oncology Symposium: Newly diagnosed lung and colorectal cancer patients indicate unmet symptom management needs.
Palliative Care in Oncology Symposium: Clinical decision support using symptom assessment, management intervention improved lung cancer outcomes.
[Cancer Management and Research] Although thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages still proves to be a therapeutic challenge. In the last several years, new therapeutic strategies have emerged.
Rolapitant in combination with granisetron and dexamethasone is effective in preventing chemotherapy-induced nausea and vomiting.
Regional disparities in cancer drug access have complex causes, including bureaucratic differences and variation in health care spending.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). The etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) are discussed.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|